Business Technology

Medtech Financings for August 2011 Pass $300 Million

Last updated: August 25, 2011 9:12 am

PatrickDriscoll

1 Min Read

In a month when the S&P devalued the stock market with its downgrade of the U.S.’ credit rating, it was encouraging to still see a strong level of investment in medical technologies, with investment in medtech at over $300 for the month.

In a month when the S&P devalued the stock market with its downgrade of the U.S.’ credit rating, it was encouraging to still see a strong level of investment in medical technologies, with investment in medtech at over $300 for the month. Top fundings included VIVUS raising $45.8 million in support of the company’s products in obesity, diabetes, apnea and others; Restoration Robotics raising $41 million for its image guidance system to be used in hair transplant procedures, Entellus Medical raising $35 million to fund development of its minimally invasive treatment of sinusitis and three separate $23 million financings for Vessix Vascular (RF balloon catheter for vascular occlusions), AccuVein (vein illumination device) and Fibrocell Sciences (autologous cell therapies).

The complete list of financings is available at link and illustrated below:

August 2011 Medtech Financings

Source: Compiled by MedMarket Diligence, LLC

TAGGED:investment medical financing medical technology

Share This Article

By PatrickDriscoll

Follow:

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.